ATE396970T1 - 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri - Google Patents

2-(1h-indolylsulfanyl)-benzylaminderivate als ssri

Info

Publication number
ATE396970T1
ATE396970T1 AT04803045T AT04803045T ATE396970T1 AT E396970 T1 ATE396970 T1 AT E396970T1 AT 04803045 T AT04803045 T AT 04803045T AT 04803045 T AT04803045 T AT 04803045T AT E396970 T1 ATE396970 T1 AT E396970T1
Authority
AT
Austria
Prior art keywords
indolylsulfanyl
ssri
benzylamine derivatives
derivatives
benzylamine
Prior art date
Application number
AT04803045T
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Jimmy Sejberg
Morten Norgaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE396970T1 publication Critical patent/ATE396970T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04803045T 2003-12-23 2004-12-21 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri ATE396970T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53259303P 2003-12-23 2003-12-23
DKPA200301923 2003-12-23

Publications (1)

Publication Number Publication Date
ATE396970T1 true ATE396970T1 (de) 2008-06-15

Family

ID=34712442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803045T ATE396970T1 (de) 2003-12-23 2004-12-21 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri

Country Status (18)

Country Link
US (4) US7563908B2 (de)
EP (1) EP1701940B1 (de)
JP (3) JP4090491B2 (de)
AT (1) ATE396970T1 (de)
AU (1) AU2004303461B2 (de)
BR (1) BRPI0417858B1 (de)
CY (2) CY1108230T1 (de)
DE (1) DE602004014190D1 (de)
DK (1) DK1701940T3 (de)
ES (1) ES2303960T3 (de)
HR (2) HRP20080274T3 (de)
IL (1) IL176111A (de)
MX (1) MXPA06007172A (de)
PL (1) PL1701940T3 (de)
PT (1) PT1701940E (de)
RS (1) RS50589B (de)
SI (1) SI1701940T1 (de)
WO (1) WO2005061455A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50589B (sr) * 2003-12-23 2010-05-07 H. Lundbeck A/S. 2-(1h-indolilsulfanil)-benzil amin derivati kao ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
EP1996948A1 (de) * 2006-03-22 2008-12-03 H.Lundbeck A/S Verfahren zur identifizierung von verbindungen zur behandlung von depression
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
EP2074091B1 (de) 2006-09-28 2015-01-07 H. Lundbeck A/S [2-(6-fluor-1h-indol-3-ylsulfanyl)benzyl]methylamin zur behandlung von affektiven psychosen
ZA200901739B (en) * 2006-09-28 2010-06-30 Lundbeck & Co As H [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
EP2205238A4 (de) * 2007-09-24 2010-10-06 Lundbeck & Co As H Kombinationstherapie im zusammenhang mit doppeltwirkenden serotonin-zusammensetzungen
TW200938189A (en) * 2008-03-13 2009-09-16 Lundbeck & Co As H [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
BRPI0916774A2 (pt) 2008-07-15 2018-02-20 Hoffmann La Roche derivados de indolila e indazolila substituídos e usos dos mesmos
EP2606031B1 (de) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin-hemmer und anwendungen davon
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
JP2016530209A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ビニルオートタキシン阻害剤化合物
JP2016531874A (ja) 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
EP3878848A1 (de) 2013-11-22 2021-09-15 Sabre Therapeutics LLC Autotaxin-inhibierende indolverbindungen
EP4026549A1 (de) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin-inhibitoren und verwendungen davon
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003023A (en) * 1930-10-16 1935-05-28 Westinghouse Electric & Mfg Co Mercury vapor or noble gas rectifier with arc control
US3803143A (en) * 1969-09-08 1974-04-09 Eisai Co Ltd 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) * 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US4055665A (en) * 1974-11-25 1977-10-25 Merck & Co., Inc. Treating arrythmia with phenylthioaralkylamines
US4056632A (en) * 1975-07-21 1977-11-01 Burroughs Wellcome Co. 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0396827A1 (de) 1989-05-09 1990-11-14 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu 2-Phenylthiobenzylamin-Derivate und Säureadditionssalze davon
GB8912971D0 (en) * 1989-06-06 1989-07-26 Wellcome Found Halogen substituted diphenylsulfides
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2124206C (en) 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
AU2395095A (en) * 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
EP0755923B1 (de) 1995-01-23 2005-05-04 Daiichi Suntory Pharma Co., Ltd. Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
WO1997017352A1 (en) 1995-11-06 1997-05-15 Gist-Brocades B.V. De-esterification process
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
US5906078A (en) * 1996-10-09 1999-05-25 Gallagher-Kaiser Corporation Retaining strip for sheet covered enclosures
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
DE19756036A1 (de) * 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6333146B1 (en) * 1999-03-10 2001-12-25 Fuji Photo Film Co., Ltd. Methine compound and silver halide photographic material containing the same
CA2369005A1 (en) 1999-04-02 2000-10-12 Icos Corporation Inhibitors of lfa-1 binding to icams and uses thereof
WO2000066537A1 (en) 1999-04-30 2000-11-09 The Trustees Of The University Of Pennsylvania Spect imaging agents for serotonin transporters
CA2381008A1 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001027068A1 (en) * 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
US6410736B1 (en) * 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
PL199351B1 (pl) 1999-12-30 2008-09-30 Lundbeck & Co As H Związki pochodne fenylopiperazyny, zawierająca je kompozycja farmaceutyczna i ich zastosowanie
CN1437596A (zh) * 1999-12-30 2003-08-20 H·隆德贝克有限公司 苯基哌嗪基衍生物
DE60011817T2 (de) 1999-12-30 2005-07-14 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl und -tetrahydropyridyl-derivate
DE60143135D1 (de) * 2000-02-29 2010-11-04 Mediquest Therapeutics Inc Melanozyten-Tyrosinasehemmer als Aufheller von topischen Hauttypen
WO2001087293A1 (en) * 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. -secretase inhibitors
US6455738B1 (en) * 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
US20030187023A1 (en) * 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
AU2001279955A1 (en) * 2000-08-18 2002-03-04 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
AU8690901A (en) * 2000-09-01 2002-03-13 Fmc Corp Disubstituted benzenes as insecticides
AU2001288623A1 (en) * 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
EP1193268A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen
US6852816B2 (en) * 2000-10-06 2005-02-08 Biocompatibles Uk Limited Zwitterionic polymers
AU2002213467A1 (en) * 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
AU2002215027B2 (en) 2000-11-14 2006-10-05 Merck Patent Gmbh Novel uses of combined 5-HT1A agonists and serotonin reuptake inhibitors
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
EP1363890A4 (de) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Melanocortin-4-rezeptor bindende verbindungen und verfahren zu deren anwendung
JP4187642B2 (ja) 2001-06-07 2008-11-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６受容体親和性を有する新規インドール誘導体
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
CN101684091A (zh) * 2001-11-14 2010-03-31 先灵公司 类大麻苷受体配体
IL162308A0 (en) 2001-12-21 2005-11-20 Lundbeck & Co As H Aminoindane derivatives as serotonin and norepinephrine uptakeinhibitors
WO2003062290A1 (en) * 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
DE60328895D1 (de) * 2002-03-01 2009-10-01 Fujifilm Corp Farbphotographisches lichtempfindliches Silberhalogenidmaterial
JP4151842B2 (ja) * 2002-03-04 2008-09-17 独立行政法人科学技術振興機構 新規なホスホン酸アミド化合物、その製造方法及び用途
EP2557139B1 (de) * 2002-03-29 2021-05-05 Massachusetts Institute Of Technology Lichtemittierende Vorrichtung mit Halbleiternanokristallen
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
MXPA04012704A (es) * 2002-06-19 2005-03-23 Schering Corp Agonistas de los receptores canabinoides.
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2004026831A1 (en) * 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag 2,4-substituted indoles and their use as 5-ht6 modulators
JP4327091B2 (ja) * 2002-09-17 2009-09-09 エフ．ホフマン−ラ ロシュ アーゲー ２，７−置換インドール及び５−ｈｔ６モジュレーターとしてのその使用
EP1402888A1 (de) * 2002-09-18 2004-03-31 Jerini AG Verwendung von substituierte carbozyclische Verbindungen als rotamase inhibitoren
US20040266732A1 (en) * 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
US20060189519A1 (en) * 2002-09-26 2006-08-24 Karl Volz Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
US20040137389A1 (en) * 2002-12-19 2004-07-15 Kouta Fukui Heat-developable light-sensitive material
AU2003297398B2 (en) * 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
US7189501B2 (en) * 2002-12-27 2007-03-13 Fuji Photo Film Co., Ltd. Silver halide color photographic photosensitive material
DE10300098A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
WO2004069888A2 (en) * 2003-02-05 2004-08-19 Biocompatibles Uk Limited Block copolymers
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ES2423800T3 (es) * 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
WO2005035516A1 (ja) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
US7229751B2 (en) * 2003-11-20 2007-06-12 Konica Minolta Medical & Graphic, Inc. Silver salt photothermographic dry imaging material and image forming method using the same
CA2550091A1 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
RS50589B (sr) * 2003-12-23 2010-05-07 H. Lundbeck A/S. 2-(1h-indolilsulfanil)-benzil amin derivati kao ssri
SE528250C2 (sv) 2004-02-27 2006-10-03 Calignum Technologies Ab Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen
JP4569142B2 (ja) * 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
JP4448730B2 (ja) * 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
WO2006022405A1 (ja) 2004-08-24 2006-03-02 Fujifilm Corporation ハロゲン化銀カラー写真感光材料及び画像形成方法
EP1806337A4 (de) 2004-10-08 2009-11-25 Banyu Pharma Co Ltd Verfahren zur herstellung einerthioetherverbindung
WO2006063606A1 (en) 2004-12-16 2006-06-22 Pirelli & C. S.P.A. Process for manufacturing a thermoplastic elastomeric material

Also Published As

Publication number Publication date
JP2007515436A (ja) 2007-06-14
CY1108230T1 (el) 2014-02-12
SI1701940T1 (sl) 2008-10-31
CY1111733T1 (el) 2015-10-07
EP1701940B1 (de) 2008-05-28
HRP20080274T3 (en) 2008-12-31
US7737170B2 (en) 2010-06-15
IL176111A (en) 2011-10-31
JP4091648B2 (ja) 2008-05-28
ES2303960T3 (es) 2008-09-01
PT1701940E (pt) 2008-07-30
US20080214645A1 (en) 2008-09-04
EP1701940A1 (de) 2006-09-20
US20080176922A1 (en) 2008-07-24
PL1701940T3 (pl) 2008-11-28
BRPI0417858A (pt) 2007-04-27
US7737171B2 (en) 2010-06-15
US7652150B2 (en) 2010-01-26
JP2007277254A (ja) 2007-10-25
BRPI0417858B1 (pt) 2017-10-10
US20060160880A1 (en) 2006-07-20
AU2004303461A1 (en) 2005-07-07
WO2005061455A1 (en) 2005-07-07
DK1701940T3 (da) 2008-09-08
JP2008110984A (ja) 2008-05-15
RS50589B (sr) 2010-05-07
MXPA06007172A (es) 2006-08-23
IL176111A0 (en) 2006-10-05
US20080214644A1 (en) 2008-09-04
HRP20110400T1 (hr) 2011-06-30
JP4090491B2 (ja) 2008-05-28
DE602004014190D1 (de) 2008-07-10
US7563908B2 (en) 2009-07-21
AU2004303461B2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
NO20060230L (no) Nye aminobenzofenonforbindelser
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
SE0502254L (sv) Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA200602180A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1701940

Country of ref document: EP